CVS Health Corporation $CVS Stake Cut by Meyer Handelman Co.

Meyer Handelman Co. cut its holdings in shares of CVS Health Corporation (NYSE:CVS) by 13.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,072 shares of the pharmacy operator’s stock after selling 7,346 shares during the quarter. Meyer Handelman Co.’s holdings in CVS Health were worth $3,815,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CVS. Capital World Investors boosted its holdings in shares of CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares during the period. State Street Corp lifted its position in CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after buying an additional 149,701 shares in the last quarter. Capital International Investors lifted its position in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after buying an additional 302,499 shares in the last quarter. Invesco Ltd. boosted its stake in shares of CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the period. Finally, Capital Research Global Investors grew its holdings in shares of CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after acquiring an additional 2,253,531 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Morgan Stanley increased their price objective on CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Leerink Partners restated an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Piper Sandler dropped their target price on CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research report on Tuesday. Robert W. Baird lifted their price target on CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group boosted their price target on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.95.

CVS Health Price Performance

Shares of NYSE:CVS opened at $71.86 on Wednesday. The stock has a market capitalization of $91.42 billion, a P/E ratio of 52.07, a P/E/G ratio of 0.73 and a beta of 0.49. The business has a 50-day moving average of $76.29 and a two-hundred day moving average of $77.74. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the firm posted $1.19 EPS. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be given a $0.665 dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.7%. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its retail footprint in 2026 — management plans roughly 60 store openings this year (including nearly 20 smaller pharmacy‑only or “apothecary” sites) as it pivots from prior net closures; the company opened its first pharmacy‑only location in Chicago. CVS Pharmacy® celebrates opening of first pharmacy-only location in Chicago
• Positive Sentiment: Market reaction to the store strategy: coverage highlights (Bloomberg/WSJ) that CVS will open more stores than it closes in 2026 — signals management sees profitable opportunities in community pharmacy. CVS to Grow Store Footprint This Year With 60 New Locations
• Positive Sentiment: Unusually heavy call‑option activity: traders purchased ~30,223 calls (about +52% vs. average), indicating speculative bullish positioning that can amplify intraday upside.
• Neutral Sentiment: Piper Sandler trimmed its price target from $101 to $99 but kept an Overweight rating — a modest PT cut that still implies sizable upside vs. the current level, so the note is supportive but slightly cautious. Benzinga
• Neutral Sentiment: Analyst/education pieces (Zacks/Yahoo) are flagging CVS as a company to watch with earnings‑beat potential using tools like Earnings ESP — these stories can attract short‑term interest but are speculative ahead of actual results. CVS Health (CVS) Increases Yet Falls Behind Market: What Investors Need to Know
• Negative Sentiment: Regulatory/legal risk: CVS reached a proposed FTC settlement over insulin pricing — the final terms and any financial penalties or behavioral remedies remain a potential headwind. CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.